Thymus cancer
Drug research and approvals for thymus cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 30 studies of thymus cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 30
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Radiation Therapy and Thymus Function in Young Women With Breast CancerNCT07725172 · Not reported · Duke University · starts Nov 1, 2026
- Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic CarcinomaNCT07598955 · Phase 1 / Phase 2 · Beijing Biotech · starts Mar 2, 2026
- CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine TumorsNCT07429851 · Not reported · European Institute of Oncology · starts Jan 1, 2026
- Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic CarcinomaNCT07324629 · Phase 2 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · starts Mar 13, 2026
- An International Study on Pediatric Patients With Rare Tumors.NCT07072143 · Not reported · Azienda Ospedaliera di Padova · starts Jan 25, 2025
- Prospective Data Collection Initiative on Thoracic MalignanciesNCT06996249 · Not reported · Dutch Society of Physicians for Pulmonology and Tuberculosis · starts Aug 15, 2025
- Ivonescimab for the Treatment of Thymic CancerNCT06980077 · Phase 2 · Jonsson Comprehensive Cancer Center · starts Jul 15, 2025
- Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors…NCT06885697 · Phase 1 · National Cancer Institute (NCI) · starts Jul 8, 2025
- Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic CarcinomaNCT06838910 · Phase 2 · The First Affiliated Hospital with Nanjing Medical University · starts Mar 31, 2025
Phase 3 1
- CisplatinDNA inhibitor
Phase 2 12 of 30
- PaclitaxelThymoma · Tubulin inhibitor
- PembrolizumabThymoma · Programmed cell death protein 1 inhibitor
- CarboplatinThymoma · DNA inhibitor
- SunitinibThymoma · Macrophage colony stimulating factor receptor inhibitor
- CyclophosphamideThymoma · DNA inhibitor
- RamucirumabThymoma · Vascular endothelial growth factor receptor 2 inhibitor
- SelinexorThymoma · Exportin-1 inhibitor
- ErfonrilimabThymoma · Cytotoxic T-lymphocyte protein 4 inhibitor
- EpirubicinThymoma · DNA inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- Sacituzumab govitecanThymoma · Tumor-associated calcium signal transducer 2 binding agent
- BevacizumabThymoma · Vascular endothelial growth factor A inhibitor
Phase 1 or earlier 4
- DoxorubicinThymoma · DNA topoisomerase II alpha inhibitor
- BosutinibThymoma · Tyrosine-protein kinase ABL inhibitor
- ImatinibThymoma · Tyrosine-protein kinase ABL inhibitor
- Povidone-iodineThymoma
How its trials ended
96 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 19 whose ending is known, 26% met their primary endpoint, 11% missed it and 63% stopped early.
- Ongoing3334%
- Completed, result not reported2930%
- Status unknown1516%
- Met its primary endpoint55%
- Stopped: other or unclear55%
- Stopped: enrollment or feasibility44%
- Missed its primary endpoint22%
- Stopped: lack of efficacy22%
- Stopped: sponsor or business decision11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA